These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28711650)

  • 1. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
    Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
    Ma C; Lowenthal BM; Pai RK
    Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
    Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
    Berg KB; Schaeffer DF
    Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
    Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
    Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
    Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
    Chiesa-Vottero A
    Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
    Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
    Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
    Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
    Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
    McCluggage WG; Shah R; Connolly LE; McBride HA
    Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
    Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
    Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
    Dabir PD; Svanholm H; Christiansen JJ
    APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
    Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
    Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma.
    Schwartz LE; Khani F; Bishop JA; Vang R; Epstein JI
    Am J Surg Pathol; 2016 Jan; 40(1):27-35. PubMed ID: 26426382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
    Ordóñez NG
    Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
    Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.